Exelixis Layoffs 2025. New focus will be on the clinical trials. Against the backdrop of a positive opening to this week's big biotech conference in san francisco, cancer drug developer exelixis inc.
New focus will be on the clinical trials. Exelixis total number of employees in 2023 was 1,310, a 7.11% increase from 2022.
Exelixis Faced Financial Challenges And The Need For Strategic Restructuring To Realign Its Priorities And Streamline.
It expects to substantially complete the restructuring in the first quarter of.
Exelixis To Cut 13% Of Jobs, Repurchase Up To Addl $450 Mln Of Shares;
Exelixis recently reported solid but not stellar 2023 financial results and provided guidance for 2024.
Exelixis Layoffs 2025 Images References :
Exelixis Is Laying Off 175 Employees, Or 13% Of Its Workforce, To “Rebalance Resources” With A Focus On Candidates Closer To Market.
Shares of midcap biotechnology company exelixis ( nasdaq:
Exelixis Inc Decided To Cut About 70% Of Its Workforce After A Cancer Drug Failed A Study.
The stream of new year layoffs that have greeted biotech employees shows no sign of abating, with exelixis announcing that around 175 of its staff will be heading for the exits in the coming.